Abstract | OBJECTIVE: SUBJECTS AND METHODS: Faecal calprotectin level was measured in 72 children with paediatric IBD in clinical remission (median age 13 years). Of these, 37 children had been in clinical remission for more than a year, 20 for 6-12 months and 15 for 3 to <6 months. The clinical outcome of the patients was followed up to the first relapse or up to 12 months. RESULTS: When in clinical remission, 35% (25/72) of the children had normal faecal calprotectin (<100 microg/g) and 13% (9/72) a very high level (>1000 microg/g) while not reporting symptoms. A clinical relapse occurred in 35% (25/72) during the subsequent 12 months. When in clinical remission, the predictive value of faecal calprotectin for an overt relapse was low ranging from 0.396 to 0.429 for faecal calprotectin values >100 microg/g or >1000 microg/g, respectively. The negative predictive value was 0.75 for values <100 microg/g. CONCLUSIONS: In paediatric IBD, subjective symptoms and clinical assessment associate poorly with the levels of faecal calprotectin. During maintenance medication in colonic disease, the probability of staying in clinical remission for a subsequent year is high if faecal calprotectin value is low.
|
Authors | Taina Sipponen, Kaija-Leena Kolho |
Journal | Scandinavian journal of gastroenterology
(Scand J Gastroenterol)
Vol. 45
Issue 7-8
Pg. 872-7
(Aug 2010)
ISSN: 1502-7708 [Electronic] England |
PMID | 20377469
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Leukocyte L1 Antigen Complex
|
Topics |
- Adolescent
- Biomarkers
- Child
- Feces
(chemistry)
- Female
- Humans
- Inflammatory Bowel Diseases
(physiopathology)
- Leukocyte L1 Antigen Complex
(analysis)
- Male
- Severity of Illness Index
|